<DOC>
	<DOCNO>NCT00828542</DOCNO>
	<brief_summary>The purpose study assess safety etonogestrel-releasing subdermal implant ( Implanon ) insert immediate puerperium healthy woman .</brief_summary>
	<brief_title>Safety Etonogestrel-Releasing Implant During Puerperium Healthy Women</brief_title>
	<detailed_description>Many contraceptive method currently available . However , 50 % pregnancy world plan , occur develop country . Long-lasting reversible contraceptive etonogestrel implant represent option reduction unwanted pregnancy , especially among patient risk short intergestational period . In addition preventing undesired pregnancy , method impact reduction maternal-fetal morbidity-mortality know associate short interval , also minimize malnutrition cycle poverty cause multiparity . On basis inclusion exclusion criterion , select 40 puerperae age 18 35 year Low Risk Prenatal Care Program University Hospital Ribeirão Preto , University São Paulo ( HC-FMRP ) . The subject randomize two type treatment ( etonogestrel-releasing implant insert 24 48 hour delivery 150 mg medroxyprogesterone administer every three month start 6 week delivery ) . Blood sample ( 40 mL ) collect single procedure patient store late determination multiple hemostatic metabolic variable 24-48 hour 6 12 week delivery . Data maternal neonatal clinical parameter also collect .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>age 18 35 year Postpartum contraception desire smoking , alcoholism drug addiction presence systemic disease ( DM2 , CVD , autoimmune disease , liver disease , thyroid disease , congenital renal hyperplasia ) body mass index ≥ 30 kg/m2 personal history arterial venous thrombosis use medication might interfere blood coagulation assessment haemostatic inflammatory variable present alteration hepatic enzyme allergic local anaesthetic ( xylocaine )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Adverse Effects</keyword>
	<keyword>Etonogestrel</keyword>
	<keyword>Postpartum period</keyword>
	<keyword>Contraception</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Metabolism</keyword>
</DOC>